Keyword: Vertex Pharmaceuticals
After a year's delay, Editas Medicine will start enrolling patients in a phase 1/2 trial of its CRISPR-based treatment for LCA10, a rare form of blindness.
The lack of efficacy seen in the phase 2b is another, potentially terminal, blow to the prospects of the Rho inhibitor.
The FDA lifted a clinical hold it placed on Vertex and CRISPR Therapeutics’ gene-edited stem cell therapy for sickle cell disease.
Inscripta aims to broaden access to CRISPR by offering new enzymes for free, and to boost R&D by outfitting scientists with a full suite of tools.
CRISPR Therapeutics and Vertex Pharmaceuticals will test their gene therapy in patients with beta thalassemia.
The partnership will leverage a platform that collates and analyzes genotype-phenotype studies to uncover insights into the underpinnings of disease.
Gilead's clinical director joins Nimbus to lead discovery; Immunocore’s CMO jumps to Tmunity; Kite taps Eisai vet to lead CAR-T sales.
Syntimmune has named Vertex’s Mario Saltarelli as chief medical officer, following several leadership changes at the company over the past 18 months.
The action prompted Galapagos to review the future of its relationship with AbbVie—and provided a boost to cystic fibrosis rival Vertex.
Vertex's newly expanded site covers 170,000 square feet, boosting Vertex’s ability to hunt for the next generation of blockbusters.